JP2024534488A5 - - Google Patents

Info

Publication number
JP2024534488A5
JP2024534488A5 JP2024517157A JP2024517157A JP2024534488A5 JP 2024534488 A5 JP2024534488 A5 JP 2024534488A5 JP 2024517157 A JP2024517157 A JP 2024517157A JP 2024517157 A JP2024517157 A JP 2024517157A JP 2024534488 A5 JP2024534488 A5 JP 2024534488A5
Authority
JP
Japan
Prior art keywords
composition
use according
target
effective dose
per
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534488A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/076516 external-priority patent/WO2023044398A1/en
Publication of JP2024534488A publication Critical patent/JP2024534488A/ja
Publication of JP2024534488A5 publication Critical patent/JP2024534488A5/ja
Pending legal-status Critical Current

Links

JP2024517157A 2021-09-16 2022-09-15 ジストロフィノパチーを処置するための筋標的化複合体の投与 Pending JP2024534488A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163245162P 2021-09-16 2021-09-16
US63/245,162 2021-09-16
US202163250177P 2021-09-29 2021-09-29
US63/250,177 2021-09-29
US202163293619P 2021-12-23 2021-12-23
US63/293,619 2021-12-23
US202263348876P 2022-06-03 2022-06-03
US63/348,876 2022-06-03
PCT/US2022/076516 WO2023044398A1 (en) 2021-09-16 2022-09-15 Dosing of muscle targeting complexes for treating dystrophinopathies

Publications (2)

Publication Number Publication Date
JP2024534488A JP2024534488A (ja) 2024-09-20
JP2024534488A5 true JP2024534488A5 (cg-RX-API-DMAC7.html) 2025-09-25

Family

ID=85603633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517157A Pending JP2024534488A (ja) 2021-09-16 2022-09-15 ジストロフィノパチーを処置するための筋標的化複合体の投与

Country Status (9)

Country Link
US (1) US20250018050A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401777A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534488A (cg-RX-API-DMAC7.html)
KR (1) KR20240058160A (cg-RX-API-DMAC7.html)
AU (1) AU2022345986A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230451A1 (cg-RX-API-DMAC7.html)
IL (1) IL311507A (cg-RX-API-DMAC7.html)
MX (1) MX2024003373A (cg-RX-API-DMAC7.html)
WO (1) WO2023044398A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2025255283A1 (en) * 2024-06-07 2025-12-11 Dyne Therapeutics, Inc. Dosing of muscle targeting complexes for treating facioscapulohumeral muscular dystrophy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1220154A1 (zh) * 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
JP2019516679A (ja) * 2016-05-04 2019-06-20 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 生物活性剤に関する方法および組成物
US20190330626A1 (en) * 2016-07-15 2019-10-31 Ionis Pharmaceuticals, Inc. Compounds and methods for use in dystrophin transcript
WO2020028832A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20230111212A1 (en) * 2020-01-10 2023-04-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4087653A4 (en) * 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Similar Documents

Publication Publication Date Title
IL311507A (en) Dosing of muscle targeting complexes for the treatment of dystrophinopathy
IL309936A (en) Muscle targeting complexes and formulations for treating dystrophinopathies
JP2025512468A5 (cg-RX-API-DMAC7.html)
IL316206A (en) Dosage of muscle targeting complexes for the treatment of myotonic dystrophy
US20200277365A1 (en) Antagonist antibodies against gdf-8 and uses therefor
JP2024160045A5 (cg-RX-API-DMAC7.html)
JP2024527362A5 (cg-RX-API-DMAC7.html)
JP2024540199A5 (cg-RX-API-DMAC7.html)
CN111527207B (zh) GalNAc衍生物
JP2026503873A (ja) Dmd遺伝子のエクソン45をスキップするための筋肉標的化複合体およびその使用
JP2024525612A5 (cg-RX-API-DMAC7.html)
JP2024525611A5 (cg-RX-API-DMAC7.html)
JP2023510350A5 (cg-RX-API-DMAC7.html)
JP2025512469A5 (cg-RX-API-DMAC7.html)
JP2024524222A5 (cg-RX-API-DMAC7.html)
JP2025512469A (ja) 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
JP6949012B2 (ja) B型肝炎表面抗原に対する抗体及びその使用
JP2025515092A5 (cg-RX-API-DMAC7.html)
JP2009529915A5 (cg-RX-API-DMAC7.html)
EP4696331A1 (en) Anti-cdh6 antibody-drug conjugate and use thereof
JP2023534422A (ja) B型肝炎ウイルスの表面抗原に結合する抗体及びその使用
US20200318113A1 (en) Polynucleotide conjugates and uses thereof
TW202535930A (zh) 同功型選擇性抗-TGF-β 抗體及其使用方法
JP2022527272A (ja) 組み合わせ免疫調節及びその使用
WO2025242061A1 (zh) 抗her2抗体药物偶联物治疗胆道癌的用途